Literature DB >> 11491168

Type II alveolar epithelial cells and interstitial fibroblasts express connective tissue growth factor in IPF.

L H Pan1, K Yamauchi, M Uzuki, T Nakanishi, M Takigawa, H Inoue, T Sawai.   

Abstract

Connective tissue growth factor (CTGF) is a growth and chemotactic factor for fibroblasts encoded by an immediate early gene that is transcriptionally activated by transforming growth factor-beta. Previous studies have shown that both CTGF messenger ribonuclear acid (mRNA) and protein are expressed in renal fibrosis and bleomycin-induced pulmonary fibrosis in mice. The aim of the present study was to investigate the localization of CTGF protein and its mRNA expression in the fibrotic lung tissue of patients with idiopathic pulmonary fibrosis (IPF). Using human fibrotic lung tissue obtained from eight autopsy cases and four biopsy cases with IPF, immunohistochemical staining, in situ hybridization, and reverse transcription-polymerase chain reaction (RT-PCR) were performed. The cellular immunoreactivity for CTGF was markedly increased in the lung tissue of patients with IPF, compared to normal lungs. The immunolocalization of CTGF was confined predominantly to proliferating type II alveolar epithelial cells and activated fibroblasts. In the normal lung, type II alveolar epithelial cells stained for CTGF were sparsely distributed. CTGF mRNA was localized in proliferating type II alveolar epithelial cells and activated fibroblasts in the interstitium of fibrotic lung tissues. RT-PCR analysis showed that CTGF mRNA was expressed at a higher level in fibrotic lungs than in normal lungs. In both an autocrine and a paracrine manner, type II alveolar epithelial cells and activated fibroblasts may play a critical role in pulmonary fibrosis by producing connective tissue growth factor which modulates fibroblast proliferation and extracellular matrix production.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11491168     DOI: 10.1183/09031936.01.00074101

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  67 in total

Review 1.  Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches.

Authors:  Moisés Selman; Victor J Thannickal; Annie Pardo; David A Zisman; Fernando J Martinez; Joseph P Lynch
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 2.  Idiopathic pulmonary fibrosis-an epidemiological and pathological review.

Authors:  Andrea T Borchers; Christopher Chang; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

Review 3.  Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy.

Authors:  Jeffrey C Horowitz; Victor J Thannickal
Journal:  Treat Respir Med       Date:  2006

Review 4.  Does current knowledge explain the pathogenesis of idiopathic pulmonary fibrosis? A perspective.

Authors:  Gary W Hunninghake; Marvin I Schwarz
Journal:  Proc Am Thorac Soc       Date:  2007-08-15

5.  Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease.

Authors:  Ana L Mora; Mauricio Rojas; Annie Pardo; Moises Selman
Journal:  Nat Rev Drug Discov       Date:  2017-10-30       Impact factor: 84.694

Review 6.  Idiopathic pulmonary fibrosis: Epithelial-mesenchymal interactions and emerging therapeutic targets.

Authors:  Justin C Hewlett; Jonathan A Kropski; Timothy S Blackwell
Journal:  Matrix Biol       Date:  2018-04-03       Impact factor: 11.583

7.  Correction to: FoxD1-driven CCN2 deletion causes axial skeletal deformities, pulmonary hypoplasia, and neonatal asphyctic death.

Authors:  Lucas L Falke; Nannan He; Susana M Chuva de Sousa Lopes; Roel Broekhuizen; Karen Lyons; Tri Q Nguyen; Roel Goldschmeding
Journal:  J Cell Commun Signal       Date:  2020-03       Impact factor: 5.782

Review 8.  Beyond a Passive Conduit: Implications of Lymphatic Biology for Kidney Diseases.

Authors:  Daniyal J Jafree; David A Long
Journal:  J Am Soc Nephrol       Date:  2020-04-15       Impact factor: 10.121

9.  Fibrosis of two: Epithelial cell-fibroblast interactions in pulmonary fibrosis.

Authors:  Norihiko Sakai; Andrew M Tager
Journal:  Biochim Biophys Acta       Date:  2013-03-14

Review 10.  New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses.

Authors:  Neil Ahluwalia; Barry S Shea; Andrew M Tager
Journal:  Am J Respir Crit Care Med       Date:  2014-10-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.